Chardan Capital Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $50.00

REGENXBIO (NASDAQ:RGNX) had its price objective trimmed by Chardan Capital from $52.00 to $50.00 in a report issued on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently commented on the stock. Stifel Nicolaus raised their price objective on shares of REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Royal Bank Of Canada increased their price target on REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of REGENXBIO in a research report on Thursday, January 29th. Barclays started coverage on REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.80.

REGENXBIO Stock Down 1.8%

RGNX stock opened at $8.35 on Tuesday. The business’s 50-day moving average price is $13.18 and its 200-day moving average price is $11.39. The stock has a market cap of $422.68 million, a P/E ratio of -2.41 and a beta of 1.05. REGENXBIO has a twelve month low of $5.03 and a twelve month high of $16.19.

Institutional Trading of REGENXBIO

A number of large investors have recently added to or reduced their stakes in RGNX. AQR Capital Management LLC boosted its position in shares of REGENXBIO by 2,247.7% during the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after acquiring an additional 594,161 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in REGENXBIO by 64.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock valued at $16,709,000 after purchasing an additional 454,977 shares in the last quarter. Invenomic Capital Management LP bought a new position in REGENXBIO during the third quarter valued at $4,120,000. Integral Health Asset Management LLC grew its stake in shares of REGENXBIO by 57.1% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $10,615,000 after buying an additional 400,000 shares in the last quarter. Finally, GSK plc bought a new stake in shares of REGENXBIO in the 4th quarter worth about $3,909,000. Institutional investors own 88.08% of the company’s stock.

Key Stories Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Clear Street argues there’s still large upside to RGNX despite the FDA pushback, offering a bullish take that could attract speculative buyers. Regenxbio stock still has over 300% upside despite FDA pushback on Hunter syndrome drug: Clear Street
• Neutral Sentiment: HC Wainwright kept a “Buy” rating and a $32 price target on RGNX, which may reduce some downside pressure by signaling conviction from at least one equity research shop. MarketBeat REGENXBIO coverage
• Negative Sentiment: The U.S. Food & Drug Administration declined to approve REGENXBIO’s RGX-121 gene therapy for Hunter syndrome — the primary near-term catalyst — which directly undermines the company’s commercialization timeline and revenue prospects. US FDA rejection sends Regenxbio shares sharply lower
• Negative Sentiment: HC Wainwright sharply reduced Q3/Q4 and FY2026 EPS estimates for RGNX (moving quarterly forecasts from about ($0.22) to ($0.61) and cutting FY guidance), signaling weaker near-term financial outlook and increasing uncertainty around cash burn and financing needs. HC Wainwright research note
• Negative Sentiment: Chardan Capital lowered its expectations for RGNX, adding further sell-side skepticism and pressure on the stock’s sentiment. Chardan Capital Has Lowered Expectations for REGENXBIO
• Negative Sentiment: Investor litigation risk emerged — Pomerantz LLP opened an investigation into RGNX investors, which typically raises legal uncertainty and potential costs. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. – RGNX

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.